Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
González Castañeda, C.; Pérez Castrillón, José Luis; Casero Lambas, A.; Mazón Ramos, M.Á.; Cañibano González, M. Á.; López Bello, M.; Herreros Fernández, V. (2004)
Publisher: Elsevier Inc.
Languages: Spanish; Castilian
Types: Article
Subjects: Neumonía, Cardiovascular, Aparato - Enfermedades
Producción Científica Se ha relacionado la enfermedad arterial coronaria con infección por Chlamydia pneumoniae, pero existen pocos estudios que valoren la presencia de anticuerpos frente a este microorganismo y el pronóstico de los pacientes con cardiopatía isquémica. El objetivo de nuestro estudio fue valorar el impacto de la positividad de anticuerpos anti-Chlamydia pneumoniae en la morbimortalidad asociada a la cardiopatía isquémica.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Gupta S, Camm AJ. Chlamydia pneumoniae and coronary heart disease. Coincidence, association, or causation? BMJ 1997;314:1778-9.
    • 2. Sumpter MT, Dunn MI. Is coronary artery disease an Infectious disease? CHEST 1997;112:301-3.
    • 3. Gurfinkel EP, Seirica BM, Bozovich G. Aterosclerosis e infección ¿estamos olvidando algo? En: Picazo JJ, Bouza E, editores. Infección 1999. Bilbao: Servisistem, 2000; p. 93-122.
    • 4. Saikku P, Mattila K, Nieminen MS, Huttunen JK, Leinonen M, Ekman MR, et al. Serological evidence of an association of a novel Chlamydia. TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988;2:983-6.
    • 5. Thomas M, Wong Y, Thomas D, Ajaz M, Tsang V, Gallagher PJ, et al. Relation between direct detection of Chlamydia pneumoniae DNA in human coronary arteries at postmortem examination and histological severity (stary grading) of associated atherosclerotic plaque. Circulation 1999;99: 2733- 6.
    • 6. Esposito G, Blasi F, Allegra L, Chiesa R, Melissano G, Cosentini R, et al. Demonstration of viable Chlamydia pneumoniae in atherosclerotic plaques of carotid arteries by reverse transcriptase polymerase chain reaction. Ann Vasc Surg 1999;13:421-5.
    • 7. Azpitarte Almagro J, Cabadés O'Callaghan A, López Merino V, de los Reyes López M, San José Garagarza JM. Angina de pecho. Concepto y clasificación. Rev Esp Cardiol 1995;48:373-82.
    • 8. Mazzoli S, Tofani N, Fantini A, Semplici F, Bandini F, Salvi A, et al. Chlamydia pneumoniae antibody response in patients with acute myocardial infarction and their follow-up. American Heart Journal, 1998;125:15-20.
    • 9. Nieto FJ, Folson AR, Sorlie PD, Grayston JT, Wang SP, Chambless LE. Chlamydia pneumoniae infection and incident coronary heart disease: the atherosclerosis Risk in Comunities Study. Am J Epidemiol 1999;150:149-56.
    • 10. Hoffmeister A, Rothenbacher DP, Wanner P, Bode G, Persson K, Brenner HE, et al. Seropositivity to Chlamydia lipopolysaccharide and Chlamydia pneumoniae, systemic inflammation and stable coronary artery disease. JACC 2000;35:115-8.
    • 11. Gufinkel E, Bozovich G, Beck E, Testa E, Livellara D, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS study. Eur Heart J 1999; 20:121-7.
    • 12. Änestad G, Scheel O, Hungnes O. Chronic infections and coronary heart disease. Lancet 1997;350:1028-30.
    • 13. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997;96:404-7.
    • 14. Grundy SM, Bilheimer D, Chait A, Clark LT, Denke M, Havel RJ. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA 1993;269:3015-23.
    • 15. Rapaport E, Bilheimer DW, Chobanian AV, Hajjar DP, Hawkins CM, Hutchins GM. Triglyceride, high-density lipoprotein, and coronary heart disease. JAMA 1993;269:505-10.
    • 16. Ridker PM, Kundsin RB, Stampfer MJ, Poulin S, Hennekens CH. Prospective study Chlamydia pneumoniae IgG seropositivity and risk of future myocardial infarction. Circulation 1999;99:1161-4.
    • 17. Davidson M, Kuo CC, Middaugh JP, Campbell LA, Wang SP, Newman WP, et al. Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis. Circulation 1998;98:628-33.
    • 18. Blasi F, Consentini R, Raccanelli R, Massari FM, Arosio C, Tarsia P, et al. A possible association of Chlamydia pneumoniae infection and acute myocardial infarction in patients younger than 65 years of age. CHEST 1997;112:309-12.
    • 19. Strachan DP, Carrington D, Mendall MR, Ballam L, Morris J, Butland BK, et al. Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the Caerphilly prospective heart disease study. BMJ 1999;318:1035-40.
    • 20. Herzen LV, Isoaho R, Kivelä SL, Saikku P. Relation of C. pneumoniae antibodies to ischaemic heart disease. Finnish study finds significant association between raised IgG, but not IgA, titres and mortality. BMJ 1999;319: 1575.
    • 21. Álvarez-Sala JL, García-Casasola G. Infección por Chlamydia pneumoniae. Medicina Interna. Farreras Rozman. 1995; Vol. II. 13.ª ed., 2414-17.
    • 22. Cobos J, Fuentes F, Ruiz G, Prieto J. Procedimientos diagnósticos en enfermedades causadas por Chlamydia pneumoniae. Rev Clin Esp 1998; 198:12-8.
    • 23. Ortego M, Bustos C, Hernández-Presa MA, Tunon J, Díaz C, Hernández G, et al. Atorvastatin reduces NF-KappaB activation and chemokine espression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999;147:253-61.
    • 24. Siscovick DS, Schwartz SM, Corey L, Grayston JT, Ashley R, Wang SP, et al. Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovitus and incident myocardial infarction and coronary heart disease death in older adults; the Cardiovascular Health Study. Circulation 2000;7:2335-40.
    • 25. Zhu J, Nieto FJ, Horne BD, Anderson JL, Muhlestein JB, Epstein SE. Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation 2001;103:45-51.
    • 26. Rupprecht HJ, Blakenberg S, Bickel C, Rippin C, Hafner G, Prellwitz W, et al. Impact of viral and bacterial infectious burden on long-tern prognosis in patients with coronary artery disease. Circulation 2001;104:35-1.
    • 27. Wald NJ, Law MR, Morris JK, Zhou X, Wong Y, Ward ME. Chlamydia pneumoniae infection and mortality from ischaemic heart disease: large prospective study. BMJ 2000;321:187-8.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article